US2012064096A1PendingUtilityA1

BTLA Antibodies and Uses Thereof

48
Assignee: OLIVE DANIELPriority: Mar 17, 2009Filed: Mar 16, 2010Published: Mar 15, 2012
Est. expiryMar 17, 2029(~2.7 yrs left)· nominal 20-yr term from priority
Inventors:Daniel Olive
A61P 31/00C07K 2317/74C07K 2317/73C07K 16/2818C07K 16/2827A61K 39/3955C07K 16/2878C07K 2317/565C07K 2317/54A61P 37/04A61K 2039/505A61P 35/00C07K 2317/55Y02A50/30
48
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates to BTLA antibodies that block BTLA-HVEM interaction and uses thereof.

Claims

exact text as granted — not AI-modified
1 . A method for treatment of a human or animal body, comprising the administration of a BTLA antibody that blocks BTLA-HVEM interaction to said human or animal body. 
     
     
         2 . The method of  claim 1  wherein said administration is for the treatment of a cancer or a chronic infection. 
     
     
         3 . A vaccine for the treatment of a cancer or a chronic infection comprising a BTLA antibody that blocks BTLA-HVEM interaction. 
     
     
         4 . A kit for the treatment of a cancer or a chronic infection comprising:
 a) a BTLA antibody that blocks BTLA-HVEM interaction; and   b) a vaccine for the treatment of a cancer or a chronic infection.   
     
     
         5 . A method of  claim 1 , wherein said BTLA antibody that blocks BTLA-HVEM interaction is a BTLA antibody which is obtainable from the hybridoma accessible under CNCM deposit number I-4123 or a derivative thereof. 
     
     
         6 . A BTLA antibody which is obtainable from the hybridoma accessible under CNCM deposit number I-4123. 
     
     
         7 . A BTLA antibody that blocks BTLA-HVEM interaction which comprises the CDRs of a BTLA antibody which is obtainable from the hybridoma accessible under CNCM deposit number I-4123. 
     
     
         8 . A hybridoma accessible under CNCM deposit number I-4123. 
     
     
         9 . A method of  claim 2  wherein said BTLA antibody that blocks BTLA-HVEM interaction is a BTLA antibody which is obtainable from the hybridoma accessible under CNCM deposit number I-4123 or a derivative thereof. 
     
     
         10 . A vaccine of  claim 3  wherein said BTLA antibody that blocks BTLA-HVEM interaction is a BTLA antibody which is obtainable from the hybridoma accessible under CNCM deposit number I-4123 or a derivative thereof. 
     
     
         11 . A kit of  claim 4  wherein said BTLA antibody that blocks BTLA-HVEM interaction is a BTLA antibody which is obtainable from the hybridoma accessible under CNCM deposit number I-4123 or a derivative thereof.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.